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Once a day Concerta methylphenidate was equivalent to
3 times daily methylphenidate in children with ADHD
Pelham WE,Gnagy EM,Burrows›Maclean L, et al.Once›a›day Concerta methylphenidate versus three›times›daily
methylphenidate in laboratory and natural settings. Pediatrics 2001 Jun;107:E105.
QUESTION: In children with attention deficit hyperactivity disorder (ADHD), is once
daily extended release methylphenidate (MPH) as effective as 3 times daily dosing?
Design
Randomised (unclear allocation concealment*), blinded
(patients/parents and outcome assessors)*, placebo
controlled crossover trial with 7 days of follow up for
each treatment condition.
Setting
State University of New York at Buffalo, Buffalo, New
York, USA.
Patients
70 children between 6 and 12 years of age (mean age 9
y, 89% boys) with ADHD receiving a stable dose of MPH
for >4 weeks. Exclusion criteria included contraindica›
tion to stimulant medication, any condition that would
interfere with participation in laboratory classroom
assessment, receiving any other medication for ADHD,
and having reached menarche. 2 children were discon›
tinued from the study.
Intervention
Crossover comparison of placebo, immediate release
(IR) MPH 3 times a day (tid), and Concerta, a once daily
MPH formulation taken in the morning. Each child’s
dose concentration was based on that child’s MPH dos›
ing before the study. 3 dosing concentrations of
medication were used: 5 mg IR MPH tid/18 mg
Concerta once a day; 10 mg IR MPH tid/36 mg
Concerta once a day; and 15 mg IR MPH tid/54 mg
Concerta once a day. Children received each medication
condition for 7 days. Parents received behavioural
parent training and teachers were taught to establish a
school home daily report card.
Main outcome measures
Change in ADHD symptoms, social behaviour and aca›
demic performance in both naturalistic (home and
school) and laboratory environments (on Saturday); and
side effects.
Main results
On all measures in all settings, both drug conditions
were statistically different from placebo (p < 0.001 for all
measures) with little difference between drug conditions.
In the natural setting, effect sizes (magnitude of the drug
effects relative to placebo) on ADHD symptoms were
2.0, on oppositional defiant disorder symptoms 1.3, and
on peer relation problems 1.4. Both medications
improved behaviour as measured by teacher ratings and
individualised target behaviours. These effects contin›
ued on into the evening as measured by parent ratings.
In the laboratory setting Concerta was equivalent to IR
MPH and both were statistically different from placebo.
Effect sizes for both active drugs ranged from 0.4 to 0.8
on measures of rule violation frequency, negative behav›
iour frequency, observed disruptive behaviours, and
individualised target behaviours. Side effects on chil›
dren’s sleep and appetite were similar for the 2 drug
conditions.
Conclusion
Once a day Concerta methylphenidate was equivalent to
3 times daily methylphenidate in children with attention
deficit hyperactivity disorder.
*See glossary.
COMMENTARY
This study by Pelham et al addresses several important questions in the clinical pharma›
cological treatment of children with ADHD. Firstly, it is well known that IR stimulants
have a short duration of effect, leaving the ADHD child vulnerable to breakthrough
symptoms as plasma stimulant concentrations decline before the next dose. Secondly,
IR stimulants require multiple daily dosings, increasing the risk of medication
non›compliance, especially when the ADHD child must visit the nurse during the
school day. Thirdly, when given twice daily (the previous standard of care) the short
duration of action of IR stimulants results in after school and early evening hours where
the child’s ADHD is not supported by stimulant medication. Thus, more recent recom›
mendations have favoured 3 times daily dosing for IR stimulants such as methylpheni›
date.
The main conclusion of this study is that once daily Concerta, a long acting MPH
formulation, is equivalent to MPH 3 times a day, and both medications are better than
placebo for symptoms of ADHD. On a multiplicity of measures assessing ADHD symp›
toms, ADHD child deportment, and academic productivity using both naturalistic par›
ent and teacher observers and data from a laboratory school, improvement on ADHD
symptoms was documented for both active drug conditions. With the exception of 2
parent ratings, no differences were found on outcome measures across the IR MPH and
Concerta drug conditions, showing that once daily Concerta was equivalent to standard
3 times daily MPH treatment.
One issue that needs to be considered in evaluating the findings is that medication
was given in the context of ongoing behavioural treatment given to the child’s parents
and teachers and in the laboratory school. Although given across all 3 conditions (Con›
certa, MPH, and placebo), children in this study were receiving combined behavioural
and pharmacological treatment. That combined treatment may not be available to
ADHD children in the “real world” of clinical practice needs to be noted.
The potential for effective, once daily, long acting stimulants such as Concerta to
become the standard of care in the pharmacological treatment of ADHD is supported
by the results of this study. Equal efficacy to IR stimulants which need to be given mul›
tiple times daily, with the potential for increased compliance and ease of use clearly
makes long acting stimulants important in the clinician’s ADHD armamentarium.
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